PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

ChemAxon and AWS simplify getting scientists moving on the cloud

Paul Underwood, solution architect at Amazon Web Services (AWS), introduced the Biotech Blueprint QuickStart program on ChemAxon’s user meeting in Boston last April. The presentation starts with a brief overview of a typical informatics infrastructure and platform teams working at biotech companies.

Paul concluded that generally the teams, dedicated to create and maintain the core platform of a biotech have to face the following challenges:

  • Resource issues – either small teams or expensive consultancy services
  • Fast reaction – science urges new solutions to happen swiftly
  • Create easy, everywhere available platforms – that is move everything to the cloud.

This need moved AWS to launch their Biotech Blueprint project. The goal is to build a secure, cloud-based platform solution that allows its users to set-up and configure best-of-breed software solutions needed throughout the drug discovery process. To achieve this, AWS provides the knowledge and expertise of a secure cloud platform; and it integrates selected software vendors to cover different scientific fields.

The project started with the needs of the preclinical phase. In the chemistry field ChemAxon got selected as the top vendor to provide unambiguous, novel compound registration within the project. Paul Underwood thanked ChemAxon for “being a leader in the cloud and being a Biotech Blueprint Launch Partner.”

AWS recently has launched Biotech Blueprint, that offers an easy switch to a cloud platform. Based on initial test results the deployment process got shrinked from weeks to only 15 minutes. The biotech company’s platform team only has to click on the required software solution and upload and install the license.

Listen to the talk by Paul Underwood of AWS [https://chemaxon.com/presentation/biotech-blueprint-how-chemaxon-and-aws-simplify-getting-you-moving-on-the-cloud] introducing Biotech Blueprint. And contact ChemAxon [https://chemaxon.com/] for more details.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC